Display options
Cite
Kramer JJ, Gu L, Moreira D, et al. Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial. J Urol. 2021;207(2):417-423doi: 10.1097/JU.0000000000002199.
Kramer, J. J., Gu, L., Moreira, D., Andriole, G., Csizmadi, I., & Freedland, S. J. (2022). Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial. The Journal of urology, 207(2), 417-423. https://doi.org/10.1097/JU.0000000000002199
Kramer, Jordan J, et al. "Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial." The Journal of urology vol. 207,2 (2022): 417-423. doi: https://doi.org/10.1097/JU.0000000000002199
Kramer JJ, Gu L, Moreira D, Andriole G, Csizmadi I, Freedland SJ. Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial. J Urol. 2022 Feb;207(2):417-423. doi: 10.1097/JU.0000000000002199. Epub 2021 Sep 21. PMID: 34544265.
Copy Download .nbib Format: NLM
Share it on

J Urol. 2022 Feb;207(2):417-423. doi: 10.1097/JU.0000000000002199. Epub 2021 Sep 21.

Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial.

The Journal of urology

Jordan J Kramer, Lin Gu, Daniel Moreira, Gerald Andriole, Ilona Csizmadi, Stephen J Freedland

Affiliations

  1. Cedars-Sinai Medical Center, Los Angeles, California.
  2. Durham VA Medical Center, Durham, North Carolina.
  3. The University of Illinois College of Medicine, Chicago, Illinois.
  4. Washington University School of Medicine in St Louis, St Louis, Missouri.

PMID: 34544265 DOI: 10.1097/JU.0000000000002199

Abstract

PURPOSE: Benign prostatic hyperplasia (BPH) is a common disease often manifested by lower urinary tract symptoms (LUTS). We previously found statins were associated with modest attenuations in prostate growth over time in REDUCE. We tested whether statins were associated with LUTS incidence in asymptomatic men and LUTS progression in symptomatic men.

MATERIALS AND METHODS: We performed a post-hoc analysis of REDUCE in 3,060 "asymptomatic" men with baseline International Prostate Symptom Score (IPSS) <8 and in 2,198 symptomatic men with baseline IPSS ≥8 not taking α-blockers or 5α-reductase inhibitors. We used multivariable Cox regression models to assess associations between statin use at baseline and LUTS incidence and progression. Among asymptomatic men, incident LUTS was defined as the first reported medical or surgical treatment for BPH or sustained clinically significant LUTS (2 reports of IPSS >14). Among symptomatic men, LUTS progression was defined as IPSS increase ≥4 points from baseline, any surgical procedure for BPH, or initiation of a BPH drug.

RESULTS: Among asymptomatic and symptomatic men, 550 (18%) and 392 (18%) used statins at baseline, respectively. On multivariable analysis, statin use was not associated with LUTS incidence (HR 1.05; 95% CI 0.78-1.41, p=0.74) in asymptomatic men, or with LUTS progression (HR 1.13; 95% CI 0.96-1.33, p=0.15) in symptomatic men. Similar results were seen in the dutasteride and placebo arms when stratified by treatment assignment.

CONCLUSIONS: In REDUCE, statin use was not associated with either incident LUTS in asymptomatic men or LUTS progression in symptomatic men. These data do not support a role for statins in LUTS prevention or management.

Keywords: hydroxymethylglutaryl-CoA reductase inhibitors; hyperplasia; lower urinary tract symptoms; prostatic

Publication Types